R R

What Is Prolia?

Prolia is a prescription medication containing denosumab, a monoclonal antibody that reduces bone breakdown. It is used to treat osteoporosis and certain other conditions associated with elevated fracture risk. Prolia is administered by subcutaneous injection every six months by a healthcare professional. It works by blocking a protein involved in the formation and activity of bone-resorbing cells. Prolia carries a boxed warning for severe hypocalcemia in patients with advanced chronic kidney disease, particularly those receiving dialysis or living with chronic kidney disease-mineral and bone disorder.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Prolia?

Prolia is a prescription medication containing denosumab, a monoclonal antibody that reduces bone breakdown. It is used to treat osteoporosis and certain other conditions associated with elevated fracture risk. Prolia is administered by subcutaneous injection every six months by a healthcare professional. It works by blocking a protein involved in the formation and activity of bone-resorbing cells. Prolia carries a boxed warning for severe hypocalcemia in patients with advanced chronic kidney disease, particularly those receiving dialysis or living with chronic kidney disease-mineral and bone disorder.

read more about prolia ...

Copy this HTML:

Copy HTML Copied!

How Does Prolia Work?

Prolia binds to receptor activator of nuclear factor kappa-B ligand, commonly called RANKL. This protein stimulates the development, activity, and survival of osteoclasts, which break down bone tissue. By blocking RANKL, denosumab reduces osteoclast activity and slows bone resorption. This can increase bone mineral density and reduce fracture risk in eligible patients. Its effects are reversible after treatment ends, and bone turnover can increase substantially following discontinuation. Patients require an ongoing bone-health management plan rather than stopping Prolia without follow-up treatment.

What Conditions Does Prolia Treat?

Prolia is approved for postmenopausal women and men with osteoporosis who have a high risk of fracture. It is also used for glucocorticoid-induced osteoporosis in eligible adults and to increase bone mass in certain patients receiving androgen deprivation therapy for prostate cancer or aromatase inhibitor therapy for breast cancer. A healthcare professional evaluates bone density, previous fractures, kidney function, calcium levels, and other risk factors before treatment. Patients with advanced chronic kidney disease require specialized assessment because of the elevated risk of severe hypocalcemia.

How Is Prolia Administered?

Prolia is administered as a 60 mg subcutaneous injection once every six months into the upper arm, upper thigh, or abdomen. Healthcare professionals should correct existing hypocalcemia before treatment and assess calcium and vitamin D intake. The prescribing information generally recommends calcium 1,000 mg and at least 400 international units of vitamin D daily, unless individualized instructions are needed. Patients with advanced chronic kidney disease require additional assessment and calcium monitoring. If Prolia is discontinued, clinicians should consider transitioning to another antiresorptive treatment to reduce the risk of multiple vertebral fractures.

What Are the Side Effects and Warnings of Prolia?

Common adverse effects include back pain, joint pain, muscle pain, and pain in the arms or legs. Serious risks include severe hypocalcemia, osteonecrosis of the jaw, atypical femur fractures, serious infections, and severe skin reactions. Prolia carries a boxed warning for potentially life-threatening hypocalcemia in advanced chronic kidney disease, especially when kidney-related mineral and bone disorders are present. Stopping, delaying, or missing treatment without appropriate follow-up can increase the risk of vertebral fractures. New muscle spasms, tingling, jaw problems, severe thigh pain, or signs of infection require prompt assessment.

Common Questions About Prolia

Is Prolia the same as denosumab?

Yes. Prolia contains denosumab, a monoclonal antibody that blocks RANKL to reduce bone breakdown.

How often is Prolia administered?

Prolia is administered as a 60 mg injection beneath the skin once every six months by a healthcare professional.

Can Prolia cause low calcium levels?

Yes. Prolia can cause severe hypocalcemia, particularly in patients with advanced chronic kidney disease. Calcium assessment and monitoring are required in specified circumstances.

Can Prolia be stopped suddenly?

Stopping or delaying Prolia without another appropriate treatment can increase the risk of vertebral fractures. Patients should discuss a transition plan with their clinician before discontinuing it.

References

DailyMed - PROLIA (denosumab) injection. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=49e5afe9-a0c7-40c4-af9f-f287a80c5c88. Date Accessed November 2, 2026.

Denosumab. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK548424/. Date Accessed November 2, 2026.

Denosumab Injection. MedlinePlus. https://medlineplus.gov/druginfo/meds/a610023.html. Date Accessed November 2, 2026.

FDA Adds Boxed Warning for Increased Risk of Severe Hypocalcemia in Patients With Advanced Chronic Kidney Disease Taking Osteoporosis Medicine Prolia (Denosumab). U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-safety-communications/fda-adds-boxed-warning-increased-risk-severe-hypocalcemia-patients-advanced-chronic-kidney-disease. Date Accessed November 2, 2026.

Prolia (Denosumab): Drug Safety Communication. U.S. Food and Drug Administration. https://www.fda.gov/safety/medical-product-safety-information/prolia-denosumab-drug-safety-communication-fda-adds-boxed-warning-increased-risk-severe-hypocalcemia. Date Accessed November 2, 2026.